Related references
Note: Only part of the references are listed.Co-expression of IL-7 and PH20 promote anti-GPC3 CAR-T tumour suppressor activity in vivo and in vitro
Xingcheng Xiong et al.
LIVER INTERNATIONAL (2021)
A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC
Kaixin Du et al.
MOLECULAR THERAPY (2021)
A novel multifunctional gold nanorod-mediated and tumor-targeted gene silencing of GPC-3 synergizes photothermal therapy for liver cancer
Yanling Liu et al.
NANOTECHNOLOGY (2021)
Navigating CAR-T cells through the solid-tumour microenvironment
Andrew J. Hou et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma
Luan Sun et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
High-Specific Isolation and Instant Observation of Circulating Tumour Cell from HCC Patients via Glypican-3 Immunomagnetic Fluorescent Nanodevice
Qihui Chu et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2021)
Phase I trial of fourth-generation chimeric antigen receptor T-cells targeting glypican-3 for advanced hepatocellular carcinoma.
Weijia Fang et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
Shukui Qin et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study
Zhenggang Ren et al.
LANCET ONCOLOGY (2021)
Engineered Anti-GPC3 Immunotoxin, HN3-ABD-T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention
Bryan D. Fleming et al.
HEPATOLOGY (2020)
microRNA-485-5p inhibits the progression of hepatocellular carcinoma through blocking the WBP2/Wnt signaling pathway
Jun Gao et al.
CELLULAR SIGNALLING (2020)
Hedgehog signaling promotes sorafenib resistance in hepatocellular carcinoma patient-derived organoids
Siqi Wang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)
Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials
Donghua Shi et al.
CLINICAL CANCER RESEARCH (2020)
Glypican-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma
Sai Arun Batra et al.
CANCER IMMUNOLOGY RESEARCH (2020)
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
32A9, a novel human antibody for designing an immunotoxin and CAR-T cells against glypican-3 in hepatocellular carcinoma
Xiaoyu Liu et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2020)
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline
John D. Gordan et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma
Jianshu Wei et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
A Frizzled-Like Cysteine-Rich Domain in Glypican-3 Mediates Wnt Binding and Regulates Hepatocellular Carcinoma Tumor Growth in Mice
Na Li et al.
HEPATOLOGY (2019)
CD19 CAR T cell product and disease attributes predict leukemia remission durability
Olivia C. Finney et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3-Targeted Chimeric Antigen Receptor-Engineered T Cells in Hepatocellular Carcinoma
Ying Liu et al.
JOURNAL OF IMMUNOLOGY (2019)
Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma
Xiuqi Wu et al.
MOLECULAR THERAPY (2019)
GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis
Zefang Tang et al.
NUCLEIC ACIDS RESEARCH (2019)
Promoting Early Diagnosis and Precise Therapy of Hepatocellular Carcinoma by Glypican-3-Targeted Synergistic Chemo-Photothermal Theranostics
Weiwei Mu et al.
ACS APPLIED MATERIALS & INTERFACES (2019)
An IL-4/21 Inverted Cytokine Receptor Improving CAR-T Cell Potency in Immunosuppressive Solid-Tumor Microenvironment
Yi Wang et al.
FRONTIERS IN IMMUNOLOGY (2019)
Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity
Shengnan Yu et al.
MOLECULAR CANCER (2019)
The Role of Glypican-3 in Regulating Wnt, YAP, and Hedgehog in Liver Cancer
Aarti Kolluri et al.
FRONTIERS IN ONCOLOGY (2019)
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions
Wanghong Hu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Targeting Hedgehog signaling pathway: Paving the road for cancer therapy
Ali Salaritabar et al.
PHARMACOLOGICAL RESEARCH (2019)
DNAX-activating protein 10 co-stimulation enhances the anti-tumor efficacy of chimeric antigen receptor T cells
Ruocong Zhao et al.
ONCOIMMUNOLOGY (2019)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2018)
Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma
Min Yu et al.
MOLECULAR THERAPY (2018)
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome
Robert Q. Le et al.
ONCOLOGIST (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1-CH3 fusion protein
Zeyan Pan et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Anti-glypican-3 monoclonal antibody (codrituzumab/GC33/RO5137382) treatment enhances tumor infiltration of PD-L1-positive macrophages, and combination therapy with anti-PD-L1 monoclonal antibody promotes antitumor effects
Mika Endo et al.
CANCER RESEARCH (2018)
697PA phase I, open-label, multi-center, dose-escalation study of codrituzumab, an anti-glypican-3 monoclonal antibody, in combination with atezolizumab in patients with locally advanced or metastatic hepatocellular carcinoma
A-L Cheng et al.
ANNALS OF ONCOLOGY (2018)
Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma
Xingliang Guo et al.
FRONTIERS IN PHARMACOLOGY (2018)
HOXA-AS2 Promotes Proliferation and Induces Epithelial-Mesenchymal Transition via the miR-520c-3p/GPC3 Axis in Hepatocellular Carcinoma
Ying Zhang et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)
Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy
Chunguang Wang et al.
ONCOTARGET (2017)
NK-92 cell, another ideal carrier for chimeric antigen receptor
Wan-ning Wang et al.
IMMUNOTHERAPY (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma
Qunfeng Wu et al.
MOLECULAR THERAPY (2017)
An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors
Takahiro Ishiguro et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Codelivery of sorafenib and GPC3 siRNA with PEI-modified liposomes for hepatoma therapy
Weitong Sun et al.
BIOMATERIALS SCIENCE (2017)
Combining ERY974, a novel Tcell-redirecting bispecific antibody targeting glypican-3, with chemotherapy profoundly improved antitumor efficacy over its monotherapy in xenograft model
Yuji Sano et al.
CANCER RESEARCH (2017)
MicroRNA-542-3p inhibits the growth of hepatocellular carcinoma cells by targeting FZD7/Wnt signaling pathway
Wenhua Wu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
Iron-Oxide-Based Nanovector for Tumor Targeted siRNA Delivery in an Orthotopic Hepatocellular Carcinoma Xenograft Mouse Model
Kui Wang et al.
SMALL (2016)
Inhibitory effect of bufalin combined with Hedgehog signaling pathway inhibitors on proliferation and invasion and metastasis of liver cancer cells
Xia Sheng et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2016)
Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma
Ghassan K. Abou-Alfa et al.
JOURNAL OF HEPATOLOGY (2016)
T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice
Christina Dargel et al.
GASTROENTEROLOGY (2015)
High preoperative levels of serum glypican-3 containing N-terminal subunit are associated with poor prognosis in patients with hepatocellular carcinoma after partial hepatectomy
Yukihiro Haruyama et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
David L. Porter et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis
Wei Gao et al.
NATURE COMMUNICATIONS (2015)
Human Monoclonal Antibody Targeting the Heparan Sulfate Chains of Glypican-3 Inhibits HGF-Mediated Migration and Motility of Hepatocellular Carcinoma Cells
Wei Gao et al.
PLOS ONE (2015)
Imaging of hepatocellular carcinoma patient-derived xenografts using 89Zr-labeled anti-glypican-3 monoclonal antibody
Xiaoyang Yang et al.
BIOMATERIALS (2014)
Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma
Masafumi Ikeda et al.
CANCER SCIENCE (2014)
Inactivation of Wnt Signaling by a Human Antibody That Recognizes the Heparan Sulfate Chains of Glypican-3 for Liver Cancer Therapy
Wei Gao et al.
HEPATOLOGY (2014)
Reduced nucleic ZHX2 involves in oncogenic activation of glypican 3 in human hepatocellular carcinoma
Fang Luan et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2014)
Glypican-3 binds to Frizzled and plays a direct role in the stimulation of canonical Wnt signaling
Mariana Capurro et al.
JOURNAL OF CELL SCIENCE (2014)
Positive glypican-3 expression in early hepatocellular carcinoma predicts recurrence after hepatectomy
I-Pei Chen et al.
JOURNAL OF GASTROENTEROLOGY (2014)
Glypican-3-Targeted 89Zr PET Imaging of Hepatocellular Carcinoma
Jonathan G. Sham et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
Diagnostic role of glypican 3 and CD34 for differentiating hepatocellular carcinoma from nonmalignant hepatocellular lesions
Eman Tawfik Enan et al.
ANNALS OF DIAGNOSTIC PATHOLOGY (2013)
First-in-Man Phase I Study of GC33, a Novel Recombinant Humanized Antibody Against Glypican-3, in Patients with Advanced Hepatocellular Carcinoma
Andrew X. Zhu et al.
CLINICAL CANCER RESEARCH (2013)
A functional screening identifies five micrornas controlling glypican-3: role of mir-1271 down-regulation in hepatocellular carcinoma
Marion Maurel et al.
HEPATOLOGY (2013)
Hedgehog Signaling Pathway Regulates Autophagy in Human Hepatocellular Carcinoma Cells
Ying Wang et al.
HEPATOLOGY (2013)
Knockdown of GPC3 inhibits the proliferation of Huh7 hepatocellular carcinoma cells through down-regulation of YAP
Hui-Lai Miao et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2013)
Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia
Shukui Qin et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
Bruno Sangro et al.
JOURNAL OF HEPATOLOGY (2013)
Wnt signaling and hepatocarcinogenesis: Molecular targets for the development of innovative anticancer drugs
Floriane Pez et al.
JOURNAL OF HEPATOLOGY (2013)
Diagnostic Value of Immunohistochemical Staining of GP73, GPC3, DCP, CD34, CD31, and Reticulin Staining in Hepatocellular Carcinoma
Shuzhe Yao et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2013)
The mechanisms of Hedgehog signalling and its roles in development and disease
James Briscoe et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2013)
Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma
Mingqian Feng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican-3-derived peptide vaccination An autopsy case
Yu Sawada et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2013)
Arginase-1, HepPar-1, and Glypican-3 Are the Most Effective Panel of Markers in Distinguishing Hepatocellular Carcinoma From Metastatic Tumor on Fine-Needle Aspiration Specimens
Dana T. Timek et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2012)
Recurrence and Poor Prognosis Following Resection of Small Hepatitis B-Related Hepatocellular Carcinoma Lesions Are Associated with Aberrant Tumor Expression Profiles of Glypican 3 and Osteopontin
Ming-Chin Yu et al.
ANNALS OF SURGICAL ONCOLOGY (2012)
Phase I Trial of a Glypican-3-Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
Yu Sawada et al.
CLINICAL CANCER RESEARCH (2012)
Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma
Silvia Tremosini et al.
GUT (2012)
Oncogenic activation of glypican-3 by c-Myc in human hepatocellular carcinoma
Li Li et al.
HEPATOLOGY (2012)
Preparation and in vitro studies of MRI-specific superparamagnetic iron oxide antiGPC3 probe for hepatocellular carcinoma
Youwei Li et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2012)
Deregulation of Hippo kinase signalling in Human hepatic malignancies
Hua Li et al.
LIVER INTERNATIONAL (2012)
Glypican-3 expression and its relationship with recurrence of HCC after liver transplantation
Yu-Liang Wang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2012)
A glypican-3-derived peptide vaccine against hepatocellular carcinoma
Yu Sawada et al.
ONCOIMMUNOLOGY (2012)
Glypican-5 stimulates rhabdomyosarcoma cell proliferation by activating Hedgehog signaling
Fuchuan Li et al.
JOURNAL OF CELL BIOLOGY (2011)
Prognostic significance of circumferential cell surface immunoreactivity of glypican-3 in hepatocellular carcinoma
Kenji Yorita et al.
LIVER INTERNATIONAL (2011)
The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis
Kwang-Pyo Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Mst1 and Mst2 Maintain Hepatocyte Quiescence and Suppress Hepatocellular Carcinoma Development through Inactivation of the Yap1 Oncogene
Dawang Zhou et al.
CANCER CELL (2009)
Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma
Hirofumi Shirakawa et al.
CANCER SCIENCE (2009)
Overgrowth of a mouse model of Simpson-Golabi-Behmel syndrome is partly mediated by Indian Hedgehog
Mariana I. Capurro et al.
EMBO REPORTS (2009)
Glypican-3 expression in clear cell adenocarcinoma of the ovary
Daichi Maeda et al.
MODERN PATHOLOGY (2009)
The expression profile of glypican-3 and its relation to macrophage population in human hepatocellular carcinoma
Hirotake Takai et al.
LIVER INTERNATIONAL (2009)
Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: A tissue microarray analysis of 4,387 tissue samples
Daniel Baumhoer et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2008)
The emerging role of the Hippo pathway in cell contact inhibition, organ size control, and cancer development in mammals
Qi Zeng et al.
CANCER CELL (2008)
Anti-Glypican 3 Antibody as a Potential Antitumor Agent for Human Liver Cancer
Takahiro Ishiguro et al.
CANCER RESEARCH (2008)
Glypican-3 inhibits Hedgehog signaling during development by competing with patched for Hedgehog binding
Mariana I. Capurro et al.
DEVELOPMENTAL CELL (2008)
Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma
Jin-Ping Lai et al.
HEPATOLOGY (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis
Luca Di Tommaso et al.
HEPATOLOGY (2007)
Wnt/β-catenin signaling in development and disease
Hans Clevers
CELL (2006)
Identification of HLA-A2-or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma
H Komori et al.
CLINICAL CANCER RESEARCH (2006)
Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling
MI Capurro et al.
CANCER RESEARCH (2005)
Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice
T Nakatsura et al.
CLINICAL CANCER RESEARCH (2004)
Glypican-3: A novel serum and histochemical marker for hepatocellular carcinoma
M Capurro et al.
GASTROENTEROLOGY (2003)
Developmental roles of the glypicans
B De Cat et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2001)
Share Paper
